Analysis of centrosome abnormalities and angiogenesis in epidermal- targeted p53(172H) mutant and p53-knockout mice after chemical carcinogenesis: Evidence for a gain of function

Molecular Carcinogenesis

Volumn 23, Issue 3, 1998, Pages 185-192

  Wang, Xiao Jing ^a   Greenhalgh, David A ^a,b   Jiang, Aibo ^a   He, Dacheng ^a   Zhong, Ling ^a   Brinkley, Bill R ^a   Roop, Dennis R ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Angiogenesis; Centrosome; Gain of function; Human keratin 1; P53

Indexed keywords

KERATIN; PROTEIN P53; THROMBOSPONDIN 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CENTROSOME; CHEMICAL CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; TUMOR VASCULARIZATION;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARCINOGENS; CENTROSOME; DISEASE PROGRESSION; ENDOTHELIAL GROWTH FACTORS; GENES, P53; HUMANS; LYMPHOKINES; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; PAPILLOMA; PHENOTYPE; POINT MUTATION; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; THROMBOSPONDIN 1; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031789426     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5     Document Type: Conference Paper

References (24)

1. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878, 1994.
2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238, 1990.
3. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221, 1992.
4. Kemp CJ, Donehower LA, Bradley A, Balmain A. Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors Cell 74:813-822, 1993.
5. Greenhalgh DA, Wang XJ, Donehower LA, Roop DR. Paradoxical tumor inhibitory effect of p53 loss in transgenic mice expressing epidermal-targeted v-rasHa, v-fos, or human transforming growth factor alpha. Cancer Res 56:4413-4423, 1996.
6. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA. A mutant p53 transgene accelerates tumor development in heterozygous but not nullizygous p53-deficient mice. Nat Genet 9:305-311, 1995.
7. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet 4:42-46, 1993.
8. Hinds PW, Finlay CA, Quartin RS, et al. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: A comparison of the "hot spot" mutant phenotypes. Cell Growth Differ 1:571-580, 1990.
9. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW, Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science 256:827-830, 1992.
10. Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of p53 mutants and their role in transcriptional activation. Oncogene 8:2555-2559, 1993.
11. Dry K, Legros Y, Auguin C, Soussi T. Analysis of the most representative tumor-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J 13:3496-3504, 1994.
12. Wang XJ, Greenhalgh DA, Jiang A, et al. Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. Oncogene 17:35-45, 1998.
13. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996.
14. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265:1582-1584, 1994.
15. Kieser A, Weich HA, Brandner G, Marme D, Kolch W. Mutant p53 potentiates protein kinase C induction of vascular endothelial growth factor expression. Oncogene 9:963-969, 1994.
16. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 55:6161-6165, 1995.
17. Claffey KP, Robinson GS. Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis. Cancer Metastasis Rev 15:165-176, 1996.
18. Wang XJ, Greenhalgh DA, Lu XR, Bickenbach JR, Roop DR. TGF alpha and v-fos cooperation in transgenic mouse epidermis induces aberrant keratinocyte differentiation and stable, autonomous papillomas. Oncogene 10:279-289, 1995.
19. Wang XJ, Greenhalgh DA, Eckhardt JN, Rothnagel JA, Roop DR. Epidermal expression of transforming growth factor-alpha in transgenic mice: induction of spontaneous and 12-O-tetradecanoylphorbol-13-acetate-induced papillomas via a mechanism independent of Ha-ras activation or overexpression. Mol Carcinog 10:15-22, 1994.
20. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude G. Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747, 1996.
21. Fukasawa K, Vande Woude G. Synergy between the Mos/mitogen-activated protein kinase pathway and loss of p53 function in transformation and chromosome instability. Mol Cell Biol 17:506-518, 1997.
22. Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819, 1997.
23. Jost CA, Marin MC, Kaelin WG Jr. p73 is a human p53-related protein that can induce apoptosis. Nature 389:191-194, 1997.
24. Crook T, Vousden KH. Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 11:3935-3940, 1992.